Apathy in Dementia Methylphenidate Trial 2

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

July 15, 2020

Study Completion Date

July 15, 2020

Conditions
ApathyAlzheimer's Disease
Interventions
DRUG

Methylphenidate

Two 5mg methylphenidate over-encapsulated drug taken twice a day for 6 months (total of 20 mg methylphenidate per day), and psychosocial intervention

DRUG

Placebo

Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention

Trial Locations (10)

14620

University of Rochester, Rochester

21224

Johns Hopkins University, Baltimore

27106

Wake Forest, Winston-Salem

29401

Roper-St. Francis Healthcare, Charleston

30322

Emory, Atlanta

44106

University Hospitals- Case Medical Center, Cleveland

72114

University of Arkansas, Little Rock

85006

Banner Alzheimer's Institute, Phoenix

06510

Yale Alzheimer's Disease Research Unit, New Haven

Unknown

Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Johns Hopkins Bloomberg School of Public Health

OTHER

NCT02346201 - Apathy in Dementia Methylphenidate Trial 2 | Biotech Hunter | Biotech Hunter